Sanjay Popat, MBBS, FRCP, PhD, discusses the investigation of lurbinectedin as a second-line treatment for patients with small cell lung cancer.
Sanjay Popat, PhD, FRCP, The Royal Marsden Hospital
Advertisement
Articles by Sanjay Popat, PhD, FRCP, The Royal Marsden Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses the clinical implications of the final results of the phase 3 ALTA-1L trial in ALK-positive non–small cell lung cancer. Scroll to 0:07 in the video for Dr. Popat's topline points on the data.
Advertisement
Latest Updated Articles
Dr. Popat on the Clinical Implications of the Final Results of the ALTA-1L Trial in ALK+ NSCLCPublished: October 4th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
4
TRX103 Tr1 Cell Therapy Shows Manageable Safety and Dose-Dependent Kinetics After HLA-Mismatched HCT in Hematologic Malignancies
5